#	Pagina
attuale pagina	/open-h2020/projects/211286/index.html
-1	/open-h2020/projects/199727/deliverables.html
-2	/open-h2020/projects/226970/index.html
-3	/open-h2020/projects/194481/index.html
-4	/open-fp7/projects/108837/index.html
-5	/open-h2020/projects/199853/index.html

Opendata, web and dolomites

PlasmaCellControl SIGNED

Transcriptional control of plasma cell development and function

Total Cost €

EC-Contrib. €

Partnership

Views

PlasmaCellControl project word cloud

Explore the words cloud of the PlasmaCellControl project. It provides you a very rough idea of what is the project "PlasmaCellControl" about.

pooled vivo ranked seq few unknown antibody regulators plasmablasts acute extend mediated lived showed host vitro consisting performed plasma retrovirus immunity differentiation secreting fundamentally effector individual infected ikaros phenotypes aiolos blimp1 rosa26 deletion function potentially systematically retroviruses experiments newly proteins transcriptional proliferating regulated exception infection irf4 pathogens humoral molecular quiescent hits functions validation impaired loxp proof expressing screens cre lines cell transcription chip xbp1 optimized genes mechanisms plasmablast interesting libraries experiment crispr upregulated mutagenesis mutant cells protection players discover bhlha15 conditional sgrna implicated cas9 rna protocols recapitulated followed

Project "PlasmaCellControl" data sheet

The following table provides information about the project.

Coordinator	FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH Organization address address: CAMPUS-VIENNA-BIOCENTER 1 city: WIEN postcode: 1030 website: www.imp.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Austria [AT]
Total cost	2˙500˙000 €
EC max contribution	2˙500˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2016-ADG
Funding Scheme	ERC-ADG
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH Organization address address: CAMPUS-VIENNA-BIOCENTER 1 city: WIEN postcode: 1030 website: www.imp.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	coordinator	2˙500˙000.00

Map

Project objective

Antibody-secreting cells consisting of short-lived proliferating plasmablasts and long-lived quiescent plasma cells are essential for the acute response to infection and long-term protection of the host against pathogens. Only a few regulators (Blimp1, IRF4, XBP1, Aiolos, Ikaros and E-proteins) have been implicated in the transcriptional control of antibody-secreting cells, and their target genes, with the exception of Blimp1 and E-proteins, are still unknown. This proposal aims to systematically identify key players in the development and function of antibody-secreting cells by using the CRISPR/Cas9 and Cre/loxP methods. For this, we improved existing protocols to extend the duration of in vitro plasmablast differentiation and showed that Rosa26(Cas9/) B cells infected with Blimp1 or Xbp1 sgRNA-expressing retroviruses recapitulated the Blimp1 and Xbp1 mutant phenotypes in this proof-of-principle experiment. Moreover, Cre retrovirus-mediated deletion of Irf4, Ikaros and Aiolos strongly impaired plasmablast differentiation in this optimized system. To discover new regulators of plasma cell differentiation, CRISPR/Cas9-based screens will be performed with pooled sgRNA libraries targeting all known upregulated genes in plasmablasts and plasma cells, followed by individual validation of the best hits. Selected top-ranked genes will be analyzed in vivo by conditional mutagenesis with newly generated, plasma cell-specific Cre lines. Regulated target genes of IRF4, Ikaros, Aiolos, XBP1 and the XBP1-regulated transcription factor Bhlha15 will be identified in plasmablasts by ChIP- and RNA-seq analyses. Target genes with potentially interesting functions will be further characterized by CRISPR/Cas9- or Cre/loxP-mediated mutagenesis. These experiments will provide fundamentally new insight into the molecular mechanisms controlling the development and function of antibody-secreting cells, which are the essential effector cells of humoral immunity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PLASMACELLCONTROL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PLASMACELLCONTROL" are provided by the European Opendata Portal: CORDIS opendata.